Belantamab-Mafodotin

Brand name: Blenrep

D

Score D — Possible Hepatotoxin

Single case reports have appeared implicating this drug, but the evidence is limited.

Fewer than 3 cases have been reported in the literature. No characteristic signature has been identified, and the case reports may not have been very convincing.

Primary class Antineoplastic
Secondary class Lymphoma, B cell
FDA approval 2020
Search another medication

No article link available. Search directly at livertox.nih.gov.